Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Interferon Beta and Glatiramer Acetate Therapy
Corey A. McGraw
,
Fred D. Lublin
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
Neurology
Research output
:
Contribution to journal
›
Review article
›
peer-review
60
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Interferon Beta and Glatiramer Acetate Therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Interferon-β (IFN-β)
100%
Glatiramer Acetate
100%
Clinical Application
33%
Mechanism of Action
33%
Multiple Sclerosis
33%
Clinical Trial Design
33%
Effect Measure
33%
Tolerability
33%
Armamentarium
33%
Immune Function
33%
Relapsing-remitting multiple Sclerosis
33%
Pivotal Trial
33%
Efficacy Index
33%
Immune Dysfunction
33%
Pharmacology, Toxicology and Pharmaceutical Science
Beta Interferon
100%
Glatiramer
100%
Multiple Sclerosis
66%
Clinical Trial
33%
Tolerability
33%
Clinical Trial Design
33%
Side Effect
33%
Neuroscience
Glatiramer Acetate
100%
Beta Interferon
100%
Multiple Sclerosis
33%
Relapsing Remitting Multiple Sclerosis
33%
Side Effect
33%
Immunology and Microbiology
Beta Interferon
100%
Glatiramer Acetate
100%
Multiple Sclerosis
33%
Relapsing Remitting Multiple Sclerosis
33%